NCT03207399View on ClinicalTrials.gov

Lung Transplantation in Chronic HCV Infection With Post Transplant EPCLUSA Treatment

PHASE4TerminatedINTERVENTIONAL

Enrollment

1

Participants

Timeline

Start Date

September 15, 2017

Primary Completion Date

March 25, 2019

Study Completion Date

March 25, 2019

Conditions

Hepatitis C, ChronicLung Transplant

Interventions

DRUG

Epclusa

Patients will be treated with this drug for 12 weeks post lung transplant.

Trial Locations (1)

27710

Duke University Medical Center, Durham

Sponsors

Lead Sponsor

Duke University

All Listed Sponsors

lead

Duke University

OTHER

NCT03207399 - Lung Transplantation in Chronic HCV Infection With Post Transplant EPCLUSA Treatment | Biotech Hunter | Biotech Hunter